This document discusses acute hepatitis B infection. It notes that in individuals who test positive for HBsAg, the differential diagnosis should include acute hepatitis B, reactivation of chronic HBV, HBeAg seroconversion flare, superinfection by other hepatitis viruses, or liver injury from other causes. Within 1-2 weeks, a person may test positive for HBsAg and HBeAg, which is a marker for HBV replication. The HBV genome can remain active in blood cells for over 5 years after clinical and serological recovery from acute hepatitis B.
This document discusses acute hepatitis B infection. It notes that in individuals who test positive for HBsAg, the differential diagnosis should include acute hepatitis B, reactivation of chronic HBV, HBeAg seroconversion flare, superinfection by other hepatitis viruses, or liver injury from other causes. Within 1-2 weeks, a person may test positive for HBsAg and HBeAg, which is a marker for HBV replication. The HBV genome can remain active in blood cells for over 5 years after clinical and serological recovery from acute hepatitis B.
This document discusses acute hepatitis B infection. It notes that in individuals who test positive for HBsAg, the differential diagnosis should include acute hepatitis B, reactivation of chronic HBV, HBeAg seroconversion flare, superinfection by other hepatitis viruses, or liver injury from other causes. Within 1-2 weeks, a person may test positive for HBsAg and HBeAg, which is a marker for HBV replication. The HBV genome can remain active in blood cells for over 5 years after clinical and serological recovery from acute hepatitis B.
diagnosis should include acute hepatitis B, reactivation of chronic HBV infection, HBeAg seroconversion to anti-HBe flare, superinfection by other hepatitis viruses, and liver injury resulting from other causes. • After 1 - 2 Weeks : HBsAg and HBeAg • HBeAg -nonstructural nucleocapsid protein, is a marker of HBV replication
• The viral genome can remain in an active form in
peripheral blood mononuclear cells for more than 5 years after complete clinical and serologic recovery from acute viral hepatitis B. • In cases of accidental needlestick exposure or exposure of mucous membranes or open cuts to HBsAg-positive blood, hepatitis B immune globulin (HBIG) should be administered within 24 hours of exposure and again 25 to 30 days later to nonimmunized patients • Liver transplantation is also used for some severe cases of liver disease caused by HBV, although the new organ usually becomes infected with HBV. Epidemiology • The TTV has been associated with posttransfusion hepatitis of unknown etiology (non–A-G). • There is evidence that TTV may be transmitted not only by parenteral exposure to blood, but also by the fecal-oral route and from mother to child. Signs and Symptomas • no clear disease association • Pathogenicity of TTV has not been proven.